Beckman Coulter Receives FDA Breakthrough Device Designation for Alzheimer’s Disease Blood Test
Beckman Coulter Diagnostics, a global leader in clinical diagnostics, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter's Access p‑Tau217/B-Amyloid 1-42 plasma ratio. This blood test is designed to aid healthcare providers identify patients with amyloid pathology associated with Alzheimer's disease. https://mma.prnewswire.com/media/2607519/pTau217_2_1080x1080.jpg “We are honored to receive […]